ReviewInfection and drug resistance2026
On the Use of Immunoglobulins for Pre-exposure Prophylaxis Against COVID-19 in Immunocompromised Patients.
Review in Infection and drug resistance, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
COVID-19 remains a cause of significant mortality and morbidity for immunocompromised patients. In the current absence of effective monoclonal antibodies to SARS-CoV-2, standard commercial intravenous/subcutaneous immunoglobulin (IVIG/SCIG) lots provide an option for passive immunotherapy since these now consistently contain SARS-CoV-2-reactive antibodies. Strong mechanistic considerations and emerging observational data support the use of IVIG/SCIG as a biologically plausible option for COVID-19 pre-exposure prophylaxis (PreEP) in immunocompromised patients. In this review, we summarize the supporting evidence available and consider optimal use cases. Neutralization capacity against Omicron lineages is consistently reduced and highly variable between lots, and there is an intrinsic several-month lag between donor immunity and product infusion. The available information in literature sources consistently reflects the use of standard replacement dosing of IVIG/SCIG and does not systematically analyze COVID-19-specific safety or outcomes with dose intensification. While the available evidence suggests that IVIG/SCIG may be effective in PreEP, without dedicated randomized or well-controlled human trials, the magnitude of clinical benefit from this intervention remains uncertain, especially against contemporary Omicron sublineages.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.